Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating on Cytokinetics (NASDAQ: CYTK).The analyst commented, "Our peak sales estimates have ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE